The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial

BACKGROUND: Guselkumab, a fully human monoclonal antibody targeting the interleukin (IL)-23p19 subunit, is approved to treat adults with active psoriatic arthritis (PsA). In the Phase 3 DISCOVER-2 trial of 739 bilogico-naïve patients with active PsA, guselkumab 100 mg resulted in less radiographic p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ritchlin, Christopher T., Coates, Laura C., Mease, Philip J., van der Heijde, Désirée, Song, Jiao, Jiang, Yusang, Shawi, May, Kollmeier, Alexa P., Rahman, Proton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830619/
https://www.ncbi.nlm.nih.gov/pubmed/36627711
http://dx.doi.org/10.1186/s13063-022-06945-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830619/
https://www.ncbi.nlm.nih.gov/pubmed/36627711
http://dx.doi.org/10.1186/s13063-022-06945-y

Ejemplares similares